• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

奥希替尼致严重间质性肺疾病：一例报告。

Osimertinib-induced severe interstitial lung disease: A case report.

机构信息

Department of Endocrinology, Shu Lan (HangZhou) Hospital, Hangzhou, China.

Department of Respiratory, Shu Lan (HangZhou) Hospital, Hangzhou, China.

出版信息

Thorac Cancer. 2019 Jul;10(7):1657-1660. doi: 10.1111/1759-7714.13127. Epub 2019 Jun 26.

DOI:10.1111/1759-7714.13127
PMID:31241220
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6610285/
Abstract

Lung cancer is globally one of the leading causes of malignant tumor-related mortality and ranks as having the highest incidence found in men and second in women. Osimertinib is a drug used to target lung cancer but its toxicity is not fully understood. Here we present a case of lung adenocarcinoma in a 78-year-old man that was treated and responded favorably with Osimertinib after the failure of other therapies. Unfortunately, the patient developed severe interstitial lung disease during the treatment procedure.

摘要

肺癌是全球导致恶性肿瘤相关死亡的主要原因之一，男性肺癌发病率最高，女性发病率居第二位。奥希替尼是一种用于治疗肺癌的药物，但它的毒性尚未完全了解。在这里，我们报告了一例 78 岁男性肺腺癌病例，该患者在其他治疗方法失败后，用奥希替尼治疗并取得了良好的效果。不幸的是，该患者在治疗过程中发生了严重的间质性肺病。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/048b/6610285/98f6649e1078/TCA-10-1657-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/048b/6610285/b1f4eb94fc02/TCA-10-1657-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/048b/6610285/fe614bbb7324/TCA-10-1657-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/048b/6610285/d4ae97e3ce9d/TCA-10-1657-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/048b/6610285/98f6649e1078/TCA-10-1657-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/048b/6610285/b1f4eb94fc02/TCA-10-1657-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/048b/6610285/fe614bbb7324/TCA-10-1657-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/048b/6610285/d4ae97e3ce9d/TCA-10-1657-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/048b/6610285/98f6649e1078/TCA-10-1657-g004.jpg

相似文献

1
Osimertinib-induced severe interstitial lung disease: A case report.奥希替尼致严重间质性肺疾病：一例报告。
Thorac Cancer. 2019 Jul;10(7):1657-1660. doi: 10.1111/1759-7714.13127. Epub 2019 Jun 26.
2
Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma.回顾性分析 EGFR 突变型非小细胞肺癌患者奥希替尼诱导的间质性肺病后奥希替尼再挑战。
Invest New Drugs. 2021 Apr;39(2):571-577. doi: 10.1007/s10637-020-01005-1. Epub 2020 Sep 21.
3
Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review.奥希替尼诱导的机化性肺炎型间质性肺疾病中奥希替尼的成功再次给药：一例报告及文献综述
Intern Med. 2020 Mar 15;59(6):823-828. doi: 10.2169/internalmedicine.3689-19. Epub 2019 Nov 29.
4
Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective study.奥希替尼引起间质性肺病后阿法替尼治疗非小细胞肺癌的安全性和有效性：一项回顾性研究。
Invest New Drugs. 2020 Dec;38(6):1915-1920. doi: 10.1007/s10637-020-00963-w. Epub 2020 Jun 15.
5
Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.奥希替尼治疗 T790M 阳性晚期非小细胞肺癌日本患者：一项汇总亚组分析。
Cancer Sci. 2019 Sep;110(9):2884-2893. doi: 10.1111/cas.14120. Epub 2019 Aug 1.
6
Fatal interstitial lung disease associated with AZD9291.与AZD9291相关的致命性间质性肺疾病。
J Cancer Res Ther. 2018 Dec;14(Supplement):S1227-S1229. doi: 10.4103/0973-1482.199380.
7
Myositis in a Patient with Advanced Lung Cancer Treated with Osimertinib.奥希替尼治疗晚期肺癌患者并发的肌炎
J Thorac Oncol. 2018 Aug;13(8):e137-e139. doi: 10.1016/j.jtho.2018.03.014.
8
Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review.在一线奥希替尼治疗期间，晚期肺腺癌患者出现再生障碍性贫血：一例病例报告及文献复习。
Lung Cancer. 2020 Apr;142:120-122. doi: 10.1016/j.lungcan.2020.02.019. Epub 2020 Feb 28.
9
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody.使用抗PD1抗体治疗后奥希替尼诱发的间质性肺疾病。
Invest New Drugs. 2017 Feb;35(1):105-107. doi: 10.1007/s10637-016-0389-9. Epub 2016 Sep 6.
10
Successful Osimertinib Rechallenge with Steroid Therapy after Osimertinib-induced Interstitial Lung Disease.奥希替尼诱导的间质性肺疾病后采用类固醇治疗成功再次使用奥希替尼
Intern Med. 2018 Jan 1;57(1):91-95. doi: 10.2169/internalmedicine.8947-17. Epub 2017 Oct 16.

引用本文的文献

1
Case Report: Osimertinib-induced acute interstitial lung disease.病例报告：奥希替尼诱发的急性间质性肺病。
Front Pharmacol. 2025 Jun 5;16:1608733. doi: 10.3389/fphar.2025.1608733. eCollection 2025.
2
Drug-induced lung disease: a narrative review.药物性肺疾病：一篇叙述性综述。
J Bras Pneumol. 2024 Sep 27;50(4):e20240110. doi: 10.36416/1806-3756/e20240110. eCollection 2024.
3
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.真实世界的奥希替尼不良事件报告系统（FAERS）药物警戒研究

本文引用的文献

1
Clinical analysis of EGFR-positive non-small cell lung cancer patients treated with first-line afatinib: A Nagano Lung Cancer Research Group.一线阿法替尼治疗 EGFR 阳性非小细胞肺癌患者的临床分析：长野肺癌研究组。
Thorac Cancer. 2019 May;10(5):1078-1085. doi: 10.1111/1759-7714.13047. Epub 2019 Apr 20.
2
Cancer statistics, 2019.癌症统计数据，2019 年。
CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.
3
The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613.
Sci Rep. 2022 Nov 15;12(1):19555. doi: 10.1038/s41598-022-23834-1.
4
[Osimertinib Re-challenge for EGFR-mutant NSCLC after 
Osimertinib-induced Interstitial Lung Disease: A Case Report].奥希替尼诱导的间质性肺疾病后，EGFR突变型非小细胞肺癌患者再次使用奥希替尼治疗：一例报告
Zhongguo Fei Ai Za Zhi. 2021 Nov 20;24(11):804-807. doi: 10.3779/j.issn.1009-3419.2021.102.39.
5
Repurposing of Kinase Inhibitors for Treatment of COVID-19.激酶抑制剂在治疗 COVID-19 中的再利用。
Pharm Res. 2020 Aug 10;37(9):167. doi: 10.1007/s11095-020-02851-7.
苹果试验：AZD9291（奥希替尼）治疗表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）患者血浆T790M阳性的可行性和活性。欧洲癌症研究与治疗组织（EORTC）1613号试验
Clin Lung Cancer. 2017 Sep;18(5):583-588. doi: 10.1016/j.cllc.2017.02.005. Epub 2017 Mar 1.
4
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.奥希替尼或铂类培美曲塞用于治疗表皮生长因子受体T790M阳性肺癌
N Engl J Med. 2017 Feb 16;376(7):629-640. doi: 10.1056/NEJMoa1612674. Epub 2016 Dec 6.
5
National estimates of cancer prevalence in China, 2011.中国 2011 年癌症流行情况的全国估计数。
Cancer Lett. 2016 Jan 1;370(1):33-8. doi: 10.1016/j.canlet.2015.10.003. Epub 2015 Oct 13.
6
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.阿法替尼治疗表皮生长因子受体抑制剂耐药的非小细胞肺癌
N Engl J Med. 2015 Apr 30;372(18):1689-99. doi: 10.1056/NEJMoa1411817.
7
Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer.韩国肺癌患者获得性 EGFR 酪氨酸激酶抑制剂耐药的机制。
BMC Cancer. 2013 Dec 27;13:606. doi: 10.1186/1471-2407-13-606.
8
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.155 例 EGFR 突变型肺癌患者获得性 EGFR-TKI 治疗耐药时的肿瘤标本分析。
Clin Cancer Res. 2013 Apr 15;19(8):2240-7. doi: 10.1158/1078-0432.CCR-12-2246. Epub 2013 Mar 7.
9
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.一线厄洛替尼治疗不适合化疗的晚期非小细胞肺癌患者（TOPICAL）：一项双盲、安慰剂对照、3 期临床试验。
Lancet Oncol. 2012 Nov;13(11):1161-70. doi: 10.1016/S1470-2045(12)70412-6. Epub 2012 Oct 16.
10
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.吉非替尼或卡铂-紫杉醇用于治疗肺腺癌。
N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19.